

Equivalent of Form PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**FIRST SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet	1	of	1
-------	---	----	---

**Complete if Known**

Application Number	10/766,528
Filing Date	January 29, 2004
First Named Inventor	SALZWEDEL, Karl
Art Unit	1648
Examiner Name	HUMPHREY, Louise Wang Zhiying
Attorney Docket Number	1900.0430002/JMC/HCC

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

632401v1


Examiner Signature	/Louise Humphrey/	Date Considered	04/05/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



Equivalent of Form PTO/SB/08B (09-06)  
Approved for use through 03/31/2007. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1490PTO		<b>Complete if Known</b>			
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/766,528		
		Filing Date	January 29, 2004		
		First Named Inventor	SALZWEDEL, Karl		
		Art Unit	1648		
		Examiner Name	HUMPHREY, Louise Wang Zhiying		
Sheet	1	of	2	Attorney Docket Number	1900.0430002/JMC/HCC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
L.H.	NPL1	Accola, M.A., <i>et al.</i> , "Efficient Particle Production by Minimal Gag Constructs Which Retain the Carboxy-Terminal Domain of Human Immunodeficiency Virus Type 1 Capsid-p2 and a Late Assembly Domain," <i>J. Virol.</i> 74:5395-5402, American Society for Microbiology (2000)	
	NPL2	Adamson, C.S., <i>et al.</i> , "In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)," <i>J. Virol.</i> , published online, doi:10.1128/JVI.01369-06, 47 pages, American Society for Microbiology (September 2006)	
	NPL3	Kanamoto, T., <i>et al.</i> , "Anti-Human Immunodeficiency Virus Activity of YK-FH312 (a Betulinic Acid Derivative), a Novel Compound Blocking Viral Maturation," <i>Antimicrob. Agents Chemother.</i> 45:1225-1230, American Society for Microbiology (2001)	
	NPL4	Kashiwada, Y., <i>et al.</i> , "3,28-Di-O-(dimethylsuccinyl)-betulin Isomers as Anti-HIV Agents," <i>Bioorg. Med. Chem. Lett.</i> 11:183-185, Pergamon Press (2001)	
	NPL5	Li, F., <i>et al.</i> , "PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 100:13555-13560, National Academy of Sciences (November 2003)	
	NPL6	Li, F., <i>et al.</i> , "Determinants of activity of the HIV-1 maturation inhibitor PA-457," <i>Virology</i> , published online, doi:10.1016/j.virol.2006.07.023, 8 pages, Academic Press (December 2006)	
	NPL7	Liang, C., <i>et al.</i> , "Characterization of a Putative $\alpha$ -Helix across the Capsid-SP1 Boundary That Is Critical for the Multimerization of Human Immunodeficiency Virus Type 1 Gag," <i>J. Virol.</i> 76:11729-11737, American Society for Microbiology (November 2002)	
	NPL8	Morellet, N., <i>et al.</i> , "Helical structure determined by NMR of the HIV-1 (345-392) Gag sequence, surrounding p2: Implications for particle assembly and RNA packaging," <i>Protein Sci.</i> 14:375-386, Cold Spring Harbor Laboratory Press (February 2005)	
	NPL9	Pettit, S.C., <i>et al.</i> , "Replacement of the P1 Amino Acid of Human Immunodeficiency Virus Type 1 Gag Processing Sites Can Inhibit or Enhance the Rate of Cleavage by the Viral Protease," <i>J. Virol.</i> 76:10226-10233, American Society for Microbiology (October 2002)	
↓	NPL10	Sakalian, M., <i>et al.</i> , "3-O-(3', 3' -Dimethylsuccinyl) Betulinic Acid Inhibits Maturation of the Human Immunodeficiency virus Type 1 Gag Precursor Assembled In Vitro," <i>J. Virol.</i> 80:5716-5722, American Society for Microbiology (June 2006)	

Examiner Signature	/Louise Humphrey/	Date Considered	04/05/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/08B (09-08)  
Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/766,528
				Filing Date	January 29, 2004
				First Named Inventor	SALZWEDEL, Karl
				Art Unit	1648
				Examiner Name	HUMPHREY, Louise Wang Zhiying
Sheet	2	of	2	Attorney Docket Number	1900.0430002/JMC/HCC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
L.H.	NPL11	Schinazi, R.F., <i>et al.</i> , "Mutations in retroviral genes associated with drug resistance," in <i>International Antiviral News</i> 496:95-107, International Medical Press (1996)	
	NPL12	von Schwedler, U.K., <i>et al.</i> , "Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein," <i>J. Virol.</i> 77:5439-5450, American Society for Microbiology (May 2003)	
	NPL13	Wieggers, K., <i>et al.</i> , "Sequential Steps in Human Immunodeficiency Virus Particle Maturation Revealed by Alterations of Individual Gag Polyprotein Cleavage Sites," <i>J. Virol.</i> 72:2846-2854, American Society for Microbiology (1998)	
	NPL14	Zhou, J., <i>et al.</i> , "Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation," <i>J. Virol.</i> 78:922-929, American Society for Microbiology (January 2004)	
	NPL15	Zhou, J., <i>et al.</i> , "The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid," <i>Retrovirology</i> 1:15, published on-line, doi:10.1186/1742-4690-1-15, 25 pages, BioMed Central (June 2004)	
	NPL16	Zhou, J., <i>et al.</i> , "The Specificity of the Small-Molecule Maturation Inhibitor 3-O-{3',3'-Dimethylsuccinyl}-Betulinic Acid for HIV-1 is Determined by the Sequence of the CA-SP1 Junction of GAG," poster 26, presented at the Fifth HIV DRP Symposium: Antiviral Drug Resistance, Chantilly, VA (November 2004)	
	NPL17	Zhou, J., <i>et al.</i> , "Inhibition of HIV-1 Maturation via Drug Association with the Viral Gag Protein in Immature HIV-1 Particles," <i>J. Biol. Chem.</i> 280:42149-42155, American Society for Biochemistry and Molecular Biology (December 2005)	
	NPL18	Zhou, J., <i>et al.</i> , "HIV-1 Resistance to the Small Molecule Maturation Inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid is Conferred by a Variety of Single Amino Acid Substitutions at the CA-SP1 Cleavage Site in Gag," <i>J. Virol.</i> , published online, doi:10.1128/JVI.01626-06, 17 pages, American Society for Microbiology (October 2006)	
↓	NPL19	U.S. National Phase Patent Application No. 11/597,431, Salzweidel <i>et al.</i> , international filing date of May 24, 2005 (NOT PUBLISHED)	

Examiner Signature	/Louise Humphrey/	Date Considered	04/05/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.